Trevi Therapeutics TRVI
NASDAQ TRVI
$14.18 -0.14 (-0.98%)
At close: Oct 1, 2026 · 4:00 PM EDT

Trevi Therapeutics (TRVI) Preferred Stock Liabilities (2018 - 2019)

Updated

Trevi Therapeutics (TRVI) posted Preferred Stock Liabilities of $128.15 million for Q1 2019, down 60.7% from the prior quarter.

Analysis

Trevi Therapeutics (TRVI) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

At the end of FY2018, Trevi Therapeutics' Preferred Stock Liabilities came in at $326.19 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Trevi Therapeutics 2.04 Bn 2.04 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 128.15 Mn
Dec 31, 2018 326.19 Mn
API Access

Trevi Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=TRVI&period=max&api_key=YOUR_API_KEY